[The use of Akatinol Memantine in the treatment of gait disturbances in Parkinson's disease].

Objective: To assess the efficacy of memantine hydrochloride in the treatment of GD in PD patients.
Materials and Methods: Patients of the main group ( n =30) received memantine hydrochloride (akatinol memantine) in a dose of 20 mg/day for 3 months in addition to antiparkinsonian therapy. Patients of the comparison group ( n =25) received only antiparkinsonian drugs. Cognitive rating scales and computerized gait assessment protocol were performed in both groups twice in 3 months interval in order to examine cognitive deficit and gait parameters.
Results: The increase in MMSE scores, improvement in gait cycle phases ratio and increase of cadence according to computerized gait analysis were observed in the main group compared to the comparison group.
Conclusion: The improvement in gait achieved during the study confirms that the treatment of cortical gait disturbances in patients with PD using memantine hydrochloride is a promising area of therapy.